Published online Feb 28, 2015. doi: 10.3748/wjg.v21.i8.2294
Peer-review started: August 31, 2014
First decision: September 27, 2014
Revised: October 24, 2014
Accepted: December 22, 2014
Article in press: December 22, 2014
Published online: February 28, 2015
Processing time: 182 Days and 14.3 Hours
Anal cancers (AC) are relatively rare tumors. Their incidence is increasing, particularly among men who have sex with other men due to widespread infection by human papilloma virus. The majority of anal cancers are squamous cell carcinomas, and they are treated according to stage. In local and locally advanced AC, concomitant chemoradiation therapy based on mitomycin C and 5-Fluorouracil (5-FU) is the current best treatment, while metastatic AC, chemotherapy with 5-FU and cisplatin remains the gold standard. There are no indications for induction or maintenance therapies in locally advanced tumors. Many novel strategies, such as targeted therapies, vaccination, immunotherapy and photodynamic therapy are in clinical trials for the treatment of AC, with promising results in some indications.
Core tip: This paper will be the newest study with the most recent updates in the treatment of anal cancer. After a brief review of different treatment of localized and metastatic anal cancer, the current options as well as novel therapies and approaches in future.